Antirobe Capsules (75 mg) (Canada)

Company: Zoetis

clindamycin capsules (as clindamycin hydrochloride)

DIN 00813532

DIN 00813540

DIN 00813524

Veterinary Use Only

Antibiotic

Description

ANTIROBE capsules contain: Medicinal ingredient: Clindamycin (as clindamycin hydrochloride), which is the hydrated salt of clindamycin. Clindamycin is a semi-synthetic antibiotic produced by a 7 (S) - chloro-substitution of the 7 (R) -hydroxyl group of lincomycin, a natural origin antibiotic produced by Streptomyces lincolnensis var. lincolnensis.

Antirobe Capsules (75 mg) Indications

For the treatment of infected wounds, abscesses and dental infections caused by or associated with Staphylococcus spp., Streptococcus spp., Bacteroides spp., Fusobacterium necrophorum and Clostridium perfringens and osteomyelitis caused by Staphylococcus aureus in dogs.

Directions For Use

Infected Wounds, Abscesses and Dental Infections: 5.5 mg/kg body weight every 12 hours.

Treatment with ANTIROBE capsules may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

Osteomyelitis: 11 mg/kg body weight every 12 hours.

Treatment with ANTIROBE capsules is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

Contraindications

ANTIROBE capsules are contraindicated in dogs with a history of hypersensitivity to preparations containing clindamycin or lincomycin. In the event of a hypersensitivity reaction following the administration of this drug, immediate appropriate therapy should be instituted.

Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

CAUTIONS

1. The use of ANTIROBE capsules occasionally results in overgrowth of nonsusceptible organisms such as clostridia and yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

2. While high dose studies in rats suggest that clindamycin is not a teratogen and did not significantly affect the reproductive performance of males or females, safety in gestating bitches or breeding males has not been established.

3. Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ANTIROBE capsules should be used with caution in dogs receiving such agents.

4. Partial cross resistance has been demonstrated between clindamycin, erythromycin and macrolide antibiotics.

5. During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high-dose clindamycin therapy.

Warnings

Keep out of reach of children.

Scientific Information

Clinical Pharmacology

Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing sub-cellular elements at the ribosomal level.

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract. Dogs orally dosed with therapeutic amounts of clindamycin hydrochloride demonstrated antibacterial serum levels of the drug within 15 minutes post-dosing.

Therapeutically effective serum levels of clindamycin hydrochloride can be maintained by oral dosing at the rate of 5.5 mg/kg every 12 hours. Dogs orally dosed with clindamycin hydrochloride at 5.5 mg/kg every 12 hours during a 72 hour dosing regimen continuously maintained antibacterial serum levels of the drug. This same study revealed that average peak serum concentrations occurred 1 hour and 15 minutes after dosing. The biological half-life for clindamycin hydrochloride in dog serum is approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses.

Metabolism and Excretion: Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after ANTIROBE capsules administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-demethyl clindamycin and clindamycin sulfoxide.

Microbiology:

The following clindamycin in vitro data are available, but their clinical significance is unknown. Clindamycin has been shown to have in vitro activity against isolates of the following organisms:

Aerobic gram positive cocci, including: Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Staphylococcus intermedius, Staphylococcus simulans, Staphylococcus epidermidis, streptococci (except S. faecalis), pneumococci.

Anaerobic gram negative bacilli, including: Bacteroides species, Fusobacterium species.

Anaerobic gram positive non-sporeforming bacilli, including: Propionibacterium, Eubacterium, Actinomyces species.

Anaerobic and microaerophillic gram positive cocci, including Peptococcus species, Peptostreptococcus species, microaerophillic streptococci.

Clostridia: Most C. perfringens are susceptible, but other species, e.g., C. sporogenes and C. tertium, are frequently resistant to clindamycin.

Mycoplasma species: Most Mycoplasma species are susceptible to clindamycin. Clindamycin and erythromycin show parallel resistance. Partial cross resistance has been demonstrated between clindamycin, erythromycin and macrolide antibiotics.

In vitro susceptibility testing:

Susceptibility tests should be done on samples collected prior to initiation of therapy with ANTIROBE capsules. Clindamycin susceptibility testing is performed by using clindamycin Susceptibility Disks (clindamycin 2 µg) and clindamycin Susceptibility Powder (20 mg). A standardized disk testing procedure1 is recommended for determining susceptibility of aerobic bacteria to clindamycin. A description is contained in the clindamycin Susceptibility Disk insert. Using this method, the laboratory can designate isolates as resistant, intermediate, or susceptible. Tube or agar dilution methods may be used for aerobic and anaerobic bacteria. When the directions in the clindamycin Susceptibility Powder insert are followed, a MIC (minimal inhibitory concentration) of 1.6 µg/mL may be considered susceptible; MICs of 1.6 to 4.8 µg/mL may be considered intermediate and MICs greater than 4.8 µg/mL may be considered resistant.

¹Bauer, A.W., W.M. Kirby, J.C. Sherris and M. Turck. Antibiotic susceptibility testing by a standardized single disk method, Am. J. Clin. Path. 45:493-496, 1966. Standardized Disk Susceptibility Test, Federal Register 37:20527-29, 1972.

Toxicology and Safety:

Animal toxicity studies with clindamycin hydrochloride showed the following:

LD₅₀ I.P. Administration - Mouse, 419 mg/kg

LD₅₀ I.V. Administration - Mouse, 143 mg/kg

LD₅₀ Oral Administration - Rat, 2618 mg/kg

One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day have shown clindamycin hydrochloride to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day vomited, had anorexia, and subsequently lost weight. Safety studies in gestating bitches or breeding males have not been run, however, teratology and reproductive studies in male and female rats at 50 mg/kg and higher showed no drug related effects.

Storage

Store between 15 and 30°C.

PRESENTATION

25 mg, yellow and white capsule containing 25 mg of clindamycin. Available in bottles of 200 capsules.

75 mg, dark green and white capsule containing 75 mg of clindamycin. Available in bottles of 200 capsules.

150 mg, white and white capsule containing 150 mg of clindamycin. Available in bottles of 100 capsules.

Zoetis^® and Antirobe are registered trademarks of Zoetis or its licensors.

Zoetis Canada Inc., Kirkland QC H9H 4M7

1614-11-3

8836971

January 2025

CPN: 1198265.5